Personalized Medicine: The Future Is (Almost) Now

The move away from the blockbuster model toward ever more narrowly targeted therapeutics is slowly but surely in progress, promising to transform not just drugmaking, but the entire healthcare system.

By Heidi Parsons, Managing Editor

1 of 2 < 1 | 2 View on one page

Like an avid gardener longs for spring, I can’t wait for “personalized medicine” to blossom and burgeon. I’m a breast cancer patient — the term “survivor” is reserved for those who’ve been out of treatment and cancer-free for five years or more — and like millions of other women who’ve been diagnosed and treated “successfully,” there’s a part of me that’s always on guard, waiting for the other shoe to drop. Why? Because despite all the research that’s been done on breast cancer in recent years, many key questions about what ignites it and what determines its risk of recurrence remain unanswered.

 

Image courtesy of Michael Ermarth, FDA
Image courtesy of
Michael Ermarth, FDA

The same is true for hundreds of diseases, from cancer in its myriad forms to autoimmune diseases such as lupus and rheumatoid arthritis, to neurological disorders such as Parkinson’s and corticobasal degeneration (see “Rebel with a Cause” for more on this). Each human being has a unique DNA profile and biochemical makeup, and determining why we get sick and how best to treat us when we do is a messy, enormously complex undertaking.

The difficulties are hardly limited to the treatment of deadly diseases; even treating individual symptoms too often resembles a game of roulette. The scientists who developed non-steroidal anti-inflammatory drugs, including Cox-2 inhibitors, set out to treat chronic pain, yet post marketing, some of these drugs were found to put some patients at increased risk for heart attack or stroke. While some patients chose to sue Merck over alleged side effects from Vioxx, others are upset that it was taken off the market. Every drug has its proponents and detractors, and there is no medicine that is effective for every patient yet has never had a negative side effect in any patient.

The concept of personalized medicine — or, to use Eli Lilly President John Lechleiter’s preferred term, “targeted therapies” — offers a way forward for patients, healthcare providers and pharmaceutical manufacturers, as well as regulatory agencies, researchers, insurers and legislators. As researchers identify biomarkers that suggest who is or is not likely to respond to a given therapy, diagnostic companies are creating tests to differentiate among patients and pharma and biopharma companies are using biomarker data to inform drug development.

 

John Lechleiter, president/COO, Eli Lilly & Co.
Lechleiter

Speaking at Harvard Medical School’s recent Personalized Medicine Conference, Lechleiter addressed the role of drug manufacturers within the broader context of the healthcare industry’s move to an increasingly patient-focused system. He said that although the conventional wisdom is that drug companies will resist personalized medicine because they’re still focused on the blockbuster model, “our business model will accommodate personalized medicine — in fact, it may depend on it.”

In a separate interview, Lechleiter elaborates on that remark. He says Lilly executives “believe that pursuing tailored therapeutics is imperative” because:

  • “When we’re better able to target our products on the patients who will really benefit from them, then our value proposition will surely grow.


  • “When tailored therapeutics are used to reduce the trial-and-error nature of health care, then fewer resources will be wasted and the cost of healthcare will be more sustainable.


  • “As we begin to take advantage of the flood of health-care information and new scientific knowledge, we’ll gain a better understanding of how benefit and risk line up for individual patients.”

At Lilly today, fully 90% of molecules reaching the clinical development stage now have a biomarker strategy associated with them, Lechleiter notes. Aside from the benefits mentioned above, he says that on the R&D side, pursuing targeted therapies has already allowed the company “to weed out unpromising molecules earlier in the game; to compress development timelines; to run smaller, more focused clinical trials and to adapt them mid-stream, based on what we’re seeing; and to start exploring secondary indications more quickly. Over time, we hope that… biomarker application will [result in] shorter cycle times and lower costs in drug development.”

Lilly is not the only large pharma company working on targeted therapies, but it is an “early adopter.” In addition to its internal efforts, Lilly is involved in several collaborations to advance personalized medicine and Lechleiter points out that the company “has been trying to serve as a conductor to help put others on board."

One way Lilly has done that is by “improving the transparency around our clinical trial results in pharma,” Lechleiter explains. “In 2004, our company became the first to disclose the results of all our clinical trials via the Internet. At the time, it was a somewhat frightening step to take but, as others have followed suit, it has not only helped us to learn from each other’s work but also improved our credibility.”

1 of 2 < 1 | 2 View on one page
Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments